- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06563765
신장 섬유증의 비침습적 모니터링을 위한 FAP 표적 PET/CT
Chronic kidney disease (CKD) is an irreversible change of kidney function and structure caused by many reasons. The main threat of CKD to human health is progressive renal function decline. Delaying the progression of chronic kidney disease to end-stage renal failure is an important clinical need, and renal fibrosis is a common pathway for the progression of chronic kidney disease to end-stage renal failure. The evaluation of renal fibrosis is of great value for the course and prognosis of patients with chronic kidney disease. However, pathological detection has the disadvantages of trauma, false negative, and cannot be implemented repeatedly. At present, there is a lack of effective non-invasive, dynamic, real-time monitoring and evaluation means. A commercially available FAP-targeted imaging agent, FAPI-04, has been used for PET/CT imaging of systemic fibrosis lesions with high uptake background in normal kidneys. Although it can show severe renal fibrosis, it is not conducive to the detection rate of patients with mild-moderate fibrosis who need more accurate evaluation. The new targeted FAP imaging agent successfully constructed by our research group has proved that it can show the degree of renal fibrosis at the living level and has correlation. Therefore, this study intends to carry out a series of clinical studies on the imaging of renal fibrosis with new targeted FAP probes, evaluate the specificity and sensitivity of the new targeted FAP probes in the diagnosis of renal fibrosis, and ultimately provide a new method for clinical dynamic, non-invasive assessment and monitoring of the degree and progression of renal fibrosis.
연구 개요
상태
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, 중국
- Peking University First Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Patients with chronic kidney disease
- Renal pathology was performed within 2 weeks
Exclusion Criteria:
- Pregnant or lactating patients
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 특수 증상
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: FAP-targeting PET/CT imaging
FAP-targeting PET/CT imaging will be performed on the enrolled patients. |
FAP-targeting PET/CT imaging will be performed on the enrolled patients. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Pathological type
기간: 1 week after enrollment
|
pathological type (e.g., sclerosing IgA nephropathy) |
1 week after enrollment
|
|
Baseline serum creatinine (μmol/L)
기간: 1 month before enrollment and 1 month after enrollment
|
laboratory results |
1 month before enrollment and 1 month after enrollment
|
|
Baseline 24-hour urinary protein (g/24h)
기간: 1 month before enrollment and 1 month after enrollment
|
laboratory results |
1 month before enrollment and 1 month after enrollment
|
|
Quantified renal pathological involvement.
기간: 1 week after enrollment
|
Based on kidney biopsy sections, interstitial atrophy, interstitial inflammatory infiltration, and tubular fibrosis will be quantified. |
1 week after enrollment
|
|
Pathological MESTC score
기간: 1 week after enrollment
|
MESTC score (0-2, for IgA nephropathy patients) |
1 week after enrollment
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Follow-up serum creatinine (μmol/L)
기간: From 1 month after enrollment to 60 month after enrollment
|
laboratory results |
From 1 month after enrollment to 60 month after enrollment
|
|
Proteinuria remisssion
기간: From 1 month after enrollment to 60 month after enrollment
|
For IgA nephropathy (IgAN) patients with baseline urinary total protein (UTP) exceeding 0.5 g/24h, a reduction of UTP to below 0.5 g/24h without recurrence within 4 weeks was considered proteinuria remission. |
From 1 month after enrollment to 60 month after enrollment
|
|
Acute kidney disease remission
기간: Within 3 month after enrollment
|
For IgAN patients with AKD, AKD remission was defined as a reduction in SCr to below 75% of the peak value within 90 days after imaging. Remission was classified as complete if the difference between the last recorded SCr and baseline SCr was ≤26.5 μmol/L; otherwise, it was classified as partial. Baseline SCr was defined as the lowest value recorded within 90 days prior to hospital admission. If unavailable, the lowest SCr value within 90 days after admission was used as the baseline. |
Within 3 month after enrollment
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .